Aktuellt
SENASTE
Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54%. This means no guarantee commitments will be utilised. Mitazalimab is close to reaching phase III readiness. The key element missing is funding, which has to come from a partner.
LÄS MER
